FDA advises Rezolute meeting
FDA Recommends Rezolute Meeting Following Mixed Phase 3 Trial Data for Ersodetug
Anonymous
Key Points
1
After a March 2026 Type B meeting, the FDA requested CGM data for independent review; Rezolute submitted source and analysis datasets, summary results, and prespecified, post-hoc, and sensitivity analyses in June 2026.
2
Rezolute said participants in the ongoing sunRIZE extension have received treatment for roughly nine months to more than two years, with continued glycemic control.
3
The FDA reiterated its commitment to addressing unmet treatment needs in both congenital and tumor-related hyperinsulinism and serving those patient communities.
4
SunRIZE was a multicenter, double-blind, randomized, placebo-controlled study; congenital hyperinsulinism is a rare disorder involving excessive insulin secretion that can cause severe, unpredictable low-blood-sugar episodes.
Rezolute received an FDA recommendation for a Type B pre-BLA meeting for ersodetug, its experimental drug for congenital hyperinsulinism, a rare genetic disorder that causes dangerous blood-sugar drops. Yahoo Finance The move comes despite the drug missing its main trial goals in the Phase 3 sunRIZE study. The FDA did not yet say whether it would approve the drug, but the pre-BLA meeting is a required step before filing for official approval.
Congenital hyperinsulinism causes the pancreas to release too much insulin, leading to severe, unpredictable low-blood-sugar episodes. TipRanks Rezolute plans to meet with the FDA and then decide on its next filing strategy after it releases data from a second Phase 3 trial, called upLIFT, for a different form of the disease caused by tumors. That study results are expected this quarter.
Trial Missed Primary Goals but Showed Some Progress
The sunRIZE trial tested ersodetug in patients with congenital hyperinsulinism in a double-blind, placebo-controlled study across multiple sites. GRAFA The drug improved glycemic control — a measure of blood-sugar management — but failed to hit its primary endpoint and key secondary endpoints. These secondary goals measured low-blood-sugar events and time spent in dangerous hypoglycemia states.
The FDA reviewed additional continuous glucose monitoring data that Rezolute submitted in June 2026, after a pre-meeting in March. RTTNews The agency acknowledged that testing challenges exist in this patient population, including measurement issues with finger-stick tests and behavioral factors. Patients in the ongoing sunRIZE extension have received treatment for nine months to more than two years and continue to show improved blood-sugar control.
FDA Signals Commitment to Rare Disease Unmet Needs
Despite the trial miss, the FDA reiterated its commitment to addressing unmet treatment needs in both congenital and tumor-related hyperinsulinism. RTTNews A Type B pre-BLA meeting allows companies to meet with regulators before formally submitting a biologics license application. This meeting will help Rezolute understand the FDA's expectations and pathway forward.
Congenital hyperinsulinism remains a critical unmet need, with few approved treatments for this rare genetic condition. The FDA's recommendation of a pre-BLA meeting signals openness to further discussion about ersodetug's potential, even though the Phase 3 data fell short of its original goals.
Rezolute Weighing Strategy Based on Second Trial Results
Rezolute is waiting for Phase 3 upLIFT results, expected this quarter, before deciding whether to move forward with a BLA filing for ersodetug in congenital hyperinsulinism. RTTNews The upLIFT study tests ersodetug in tumor-related hyperinsulinism, a different disease caused by insulin-producing tumors. Success in that trial could strengthen Rezolute's overall case for the drug.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
11
Articles
23
Reach
34
A
AnonymousAuthor
